98330-15-5

Basic information

• Product Name: L-Cysteine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester
• Synonyms: N-(tert-butyloxycarbonyl)-L-cysteine tert-butyl ester;bis-N-Boc-cystine bis-tert-butyl ester;N-Boc-cysteine tert-butyl ester;(R)-2-tert-Butoxycarbonylamino-3-mercapto-propionic acid tert-butyl ester;N-BOC-L-cysteine tert-butyl ester;Boc-Cys(SH)-OtBu;Boc-Cys-OBut
• CAS NO: 98330-15-5
• Molecular Formula: C12H23NO4S
• Molecular Weight: 277.385
• Mol File: 98330-15-5.mol

Chemical Properties

• CAS DataBase Reference: L-Cysteine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Cysteine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester(98330-15-5)
• EPA Substance Registry System: L-Cysteine, N-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester(98330-15-5)

Safety Data

• Hazardous Substances Data: 98330-15-5(Hazardous Substances Data)

Upstream product

• 98303-76-5 tert-butyl (2R)-3-{[(2R)-3-(tert-butoxy)-2-{[(tert-butoxy)carbonyl]amino}-3-oxopropyl]disulfanyl}-2-{[(tert-butoxy)carbonyl]amino}propanoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 38261-78-8 (2R,2'R)-di-tert-butyl 3,3'-disulfanediylbis(2-aminopropanoate)dihydrochloride 
• 158009-01-9 tert-Butyl N^α-tert-butoxycarbonyl-L-(S-trityl)cysteinate hydrochloride 
• 10389-65-8 di-t-butoxycarbonyl-L-cystine 
• 62574-13-4 L-cystine tert-butyl ester 

Downstream Products

• 251325-31-2 1,1-dimethylethyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-S-[(1R)-1-methyl-2-({[(phenylmethyl)oxy]carbonyl}amino)ethyl]-L-cysteinate 
• 1174921-41-5 C₂₃H₃₆N₂O₆S 
• 174827-36-2 3-(2-benzyloxycarbonylamino-ethanesulfonyl)-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester 
• 157598-37-3 N-BOC-S-(2'acetoxybenzoyl)-L-cysteine tert-butyl ester 
• 98303-75-4 N¹-(benzyloxycarbonyl)-N²-(tert-butyloxycarbonyl)-L-cystine ethyl tert-butyl diester 

Relevant articles and documents

Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XLand BCL-2

The BCL-2 family of proteins (including the prosurvival proteins BCL-2, BCL-XL, and MCL-1) is an important target for the development of novel anticancer therapeutics. Despite the challenges of targeting protein-protein interaction (PPI) interfaces with small molecules, a number of inhibitors (called BH3 mimetics) have entered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, new validated chemical series are desirable. Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as α-helix mimetics. We describe structure-guided exploration of a cryptic "p5"pocket identified in BCL-XL. This work yields novel inhibitors with submicromolar binding, with marked selectivity toward BCL-XL. Extension into the hydrophobic p2 pocket yielded the most potent inhibitor in the series, binding strongly to BCL-XL and BCL-2 (nanomolar-range half-maximal inhibitory concentration (IC50)) and displaying mechanism-based killing in cells engineered to depend on BCL-XL for survival.

Investigating the Individual Importance of the Pam2Cys Ester Motifs on TLR2 Activity

TLR2 agonists are at the forefront of vaccine research for a plethora of diseases, in particular they offer a promising tool for the treatment of cancer. A detailed knowledge of their structure–activity relationship informs the methodical design of vaccin

CYSTINE DIAMIDE ANALOGS FOR CYSTINURIA

This document discloses novel cystine analogs, methods of making cystine analogs, compositions containing cystine analogs and methods of using such analogs for inhibiting cystine stone formation and treatment of cystinuria.

COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR TREATING HYPERTENSION OR HEART FAILURE

The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

MASP INHIBITORY COMPOUNDS AND USES THEREOF

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

TRIAZOLE ANTIMICROBIAL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present disclosure provides a triazole antibacterial derivative and a pharmaceutical composition thereof and a use thereof and in particular relates to a compound represented by the following formula (I), and a racemate, a stereoisomer, a tautomer, an oxynitride or a pharmaceutically acceptable salt thereof: The compound of the present disclosure has a desirable water solubility and can be formulated into an injection for use without adding a cosolvent having a potential safety risk (such as hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and the like), facilitating drug administration for patients, and greatly improving clinical safety. The drug can be used even by patients with moderate or severe renal impairment, thereby expanding the application scope of the drug.

Posaconazole derivative, pharmaceutical composition and use thereof

The present disclosure provides a posaconazole derivative, a pharmaceutical composition and use thereof, which specifically include a compound represented by the following formula (I), a racemate, stereoisomer, tautomer, oxynitride, or a pharmaceutically acceptable salt thereof: The compounds of the present disclosure have strong antifungal activity, high safety, and good water solubility, without the need for the addition of a cosolvent (such as hydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, and the like) with potential safety risks. Furthermore, the formulation process of the compound could have less difficulty and less cost, and therefore can be used to prepare improved antifungal drugs.

CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE THEREOF

Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.

Synthesis and evaluation of L-cystathionine as a standard for amino acid analysis

L-Cystathionine is a key nonprotein amino acid related to metabolic conditions. The quantitative determination of L-cystathionine in physiological fluids by amino acid analysis is important for clinical diagnosis; however, certified reference material for L-cystathionine with satisfactory purity, content, and quantity has been unavailable until recently. Consequently, a practical and simple method for the preparation of L-cystathionine was examined, which involves thioalkylation of N-tert-butoxycarbonyl-Lcysteine tert-butyl ester, derived from L-cystine, with (2S)-2-(tert-butoxycarbonyl)amino-4-iodobutanoic acid tert-butyl ester, derived from L-aspartic acid, to obtain L-cystathionine with protecting groups, followed by single-step deprotection under mild conditions. This method produces L-cystathionine in high purity (99.4%) and having sufficient percentage content according to amino acid analysis, which could be used as a standard for the amino acid analysis of physiological fluids.

Hydrazine-sensitive thiol protecting group for peptide and protein chemistry

In the search for a new Cys side-chain protecting group that is compatible to the solid-phase peptide synthesis yet can be removed under mild conditions, the Hqm and Hgm groups that are readily deprotected by using aqueous hydrazine have been developed. The utility of these groups for peptide and protein chemistry is tested by the total synthesis of a peptide antibiotic trifolitoxin and the human neutrophil defensin hNP2.